. Author manuscript; available in PMC: 2018 Feb 8.

Published in final edited form as: ACS Appl Mater Interfaces. 2018 Jan 24;10(5):4379–4393. doi: 10.1021/acsami.7b14362

Table 1. Radiodosimetry of ¹²⁵I-αMSH-PEG-Cy5-C′ dots.

in a 70-kg standard human based on the pharmacokinetics in M21 and B16F10 tumor-bearing mice and the OLINDA dosimetry program.

Tissue	Absorbed Dose (mGy/MBq)
Tissue	Based on M21 biodistribution data	Based on B16F10 biodistribution data
Adrenals	0.204	0.206
Brain	0.140	0.168
Breasts	0.129	0.147
Gallbladder Wall	0.223	0.224
Lower Large Intestine Wall	0.276	0.263
Small Intestine	0.243	0.248
Stomach Wall	0.270	0.247
Upper Large Intestine Wall	0.249	0.240
Heart Wall	0.206	0.206
Kidneys	0.324	0.242
Liver	0.335	0.251
Lungs	0.249	0.192
Muscle	0.179	0.169
Ovaries	0.204	0.226
Pancreas	0.215	0.220
Red Marrow	0.212	0.193
Bone	0.354	0.308
Skin	0.115	0.128
Spleen	0.262	0.195
Testes	0.152	0.178
Thymus	0.164	0.178
Thyroid	0.161	0.179
Urinary Bladder Wall	0.281	0.359
Uterus	0.206	0.243
Total Body	0.192	0.194
Effective Dose	0.222	0.223

Table 1. Radiodosimetry of 125I-αMSH-PEG-Cy5-C′ dots.